Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $1.1 million.

  • Pharma's Other Non Operating Income rose 240697.67% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 154800.0%. This contributed to the annual value of $325000.0 for FY2025, which is 12727.27% up from last year.
  • Latest data reveals that Pharma reported Other Non Operating Income of $1.1 million as of Q3 2025, which was up 240697.67% from $306000.0 recorded in Q2 2025.
  • In the past 5 years, Pharma's Other Non Operating Income ranged from a high of $1.1 million in Q3 2025 and a low of $4000.0 during Q3 2021
  • In the last 5 years, Pharma's Other Non Operating Income had a median value of $32000.0 in 2023 and averaged $128842.1.
  • In the last 5 years, Pharma's Other Non Operating Income crashed by 9616.25% in 2022 and then surged by 297142.86% in 2025.
  • Quarter analysis of 5 years shows Pharma's Other Non Operating Income stood at $4000.0 in 2021, then surged by 625.0% to $29000.0 in 2022, then grew by 10.34% to $32000.0 in 2023, then surged by 53.12% to $49000.0 in 2024, then skyrocketed by 2100.0% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $306000.0 for Q2 2025, and $215000.0 during Q1 2025.